Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-706 + Budigalimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-706 | ABBV706|ABBV 706 | ABBV-706 is an antibody-drug conjugate (ADC) comprising an antibody targeting SEZ6 linked to a topoisomerase I payload, which may have potential antitumor activity (Annals of Oncology 34 (2023): S1077, J Clin Oncol 42, 2024 (suppl 16; abstr 3001)). | ||
Budigalimab | ABBV181|ABBV 181|ABBV-181 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Budigalimab is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32770720). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05599984 | Phase I | ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | Recruiting | USA | ITA | ISR | FRA | ESP | DEU | AUS | 2 |